TNFSF10 and depressive symptom measurement: Despite accounting for only 7.38% of the total effect, the pro-apoptotic pathway of TRAIL directly damages cardiovascular cells, potentially amplifying plaque vulnerability in patients with depression and those with chronic inflammation.